// App-Quantinova.ai

1500 : The Small Molecule Inhibitor of VLA4 TBC3486 Sensitizes Resistant ALL to Chemotherapy

Researchers

Presenter

  • Eun Ji Gang

Principal Investigators

  • Halvard Bonig

  • Ronald J Biediger

  • Peter Vanderslice

  • Yong-Mi Kim

Medical Centers

  • Hematopoietic Cell Research Group, German Red Cross Blood Centre and Institute for Transfusion Medicine and Immunohematology, Johann-Wolfgang-Goethe University, Frankfurt, Germany

Locations

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • B-cell acute lymphoblastic leukemia

Biomarkers

  • Integrin alpha-4

  • Vascular cell adhesion molecule 1

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Asparaginase

  • Natalizumab

  • Vincristine

  • TBC-3486

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved